vcmmae

VCMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity.

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB). Glembatumumab vedotin has potent anticancer effects and can be used in the study of triple negative breast cancer (TNBC).

VcMMAE-Deruxtecan is a toxic molecular conjugate (Drug-Linker Conjugates for ADC) composed of a linker and cytotoxic agents MMAE (microtubule inhibitor) and Exatecan (DNA topoisomerase I inhibitor). This compound is employed in the synthesis of ADCs.

VcMMAE-Eribulin is a (Drug-Linker Conjugates for ADC) composed of the linker and cytotoxic molecules MMAE and Eribulin. This conjugate is used in the synthesis of ADCs.

Anti-CCL2 (Carlumab)-VcMMAE is an antibody-drug conjugate (ADC) composed of the human-derived anti-CCL2 antibody Carlumab, linked with valine-citrulline (vc) and tubulin inhibitor MMAE. The toxic moiety and linker in the ADC are McMMAE. Anti-CCL2 (Carlumab)-VcMMAE can induce apoptosis and is utilized in cancer research.

ADC Control Human IgG1 kappa-vcMMAE is a human monoclonal antibody and an isotype control for Human IgG1 kappa-vcMMAE that inhibits tubulin polymerization.

Human IgG1 (K214R) kappa-VcMMAE, ADC Control is an IgG1-based antibody-drug conjugate control containing VcMMAE. It can be used as a control in ADC.

Human IgG1 (LALAPG) kappa-VcMMAE, ADC Control is an IgG1-based antibody-drug conjugate control containing VcMMAE with Fc LALAPG modification. It can be used as a control in ADC.

Pinatuzumab vedotin is an antibody-drug conjugate (ADC) formed by conjugating the humanized anti-CD22 monoclonal antibody pinatuzumab with VcMMAE, and exhibits antitumor activity.

APL-1091 (Mal-Exo-EEVC-MMAE) is an ADC toxic molecule-linker conjugate, designed for drug-linker conjugates in ADC applications. It is composed of a Mal-Exo-EEVC linker coupled with MMAE (a microtubule inhibitor). APL-1091 is suitable for use in ADC synthesis.

Sirtratumab vedotin (ASG15-ME) is an ADC. Sirtratumab vedotin (ASG15-ME) conjugates a SLITRK6-specific human γ2 antibody (Igγ2) to the small-molecule microtubule-disrupting agent monomethylauristatin E (MMAE) via a protease-cleavable linker.

APL-1081 (Mal-Exo-EVC-MMAE) forms part of an antibody-drug conjugate (ADC). It consists of the ADC linker (peptide Mal-Exo-EEVC) coupled with the potent microtubule polymerization inhibitor MMAE.

Ozuriftamab vedotin is an antibody‑drug conjugate (ADC) composed of the conditionally active biologic (CAB) — humanized anti-receptor tyrosine kinase-like orphan receptor 2 (ROR2) monoclonal antibody Ozuriftamab — conjugated to VcMMAE, with antitumor activity.

PF-08046054 (SGN-PDL1V) is an antibody-drug conjugate (ADC) targeting PD-L1, created by linking an anti-PD-L1 antibody with the vedotin drug linker VcMMAE. This compound delivers MMAE intracellularly, exerting direct cytotoxic effects on PD-L1-expressing tumor cells. PF-08046054 is applicable for research in solid tumors.

Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. It consists of a humanized anti-PD-L1 antibody (Atezolizumab), a lysosome-cleavable dipeptide linker (valine-citrulline), and a tubulin inhibitor (MMAE), with the drug-linker conjugate being VcMMAE. This ADC exhibits potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effects. In the MC38 xenograft humanized PD-1 immune system mouse model, Atezolizumab-MMAE demonstrates significant antitumor activity.

MRG003 is an antibody-drug conjugate (ADC) composed of the humanized anti-EGFR IgG1 monoclonal antibody, Becotatug, coupled with MMAE. These components are linked through a valine-citrulline (valine-citrulline) connector, forming the Drug-Linker conjugate VcMMAE within the ADC.